About inCerebro
inCerebro is a company based in Seoul (South Korea) founded in 2019 by Minsup Kim and Art E Cho. inCerebro operates in a competitive market with competitors including BeiGene, Jazz Pharmaceuticals, Incyte, LEO Pharma and C4 Therapeutics, among others.
- Headquarter Seoul, South Korea
- Founders Minsup Kim, Art E Cho
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of inCerebro
Detailed funding history for inCerebro
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by inCerebro
Investment portfolio details for inCerebro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - inCerebro
Detailed financials for inCerebro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Incerebro Comparisons
Peer comparison for inCerebro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of inCerebro
inCerebro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Jazz Pharmaceuticals, Incyte, LEO Pharma and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of inCerebro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Incerebro
Complete news archive for inCerebro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about inCerebro
inCerebro was founded in 2019.
inCerebro is headquartered in Seoul, South Korea.
Art E Cho is the current CEO of inCerebro. They have also founded this company.
inCerebro was founded in 2019 in Seoul, South Korea, as a biotechnology firm focused on drug development. Molecular modeling and AI technologies are utilized to create therapies for cancer, metastasis inhibition, immunotherapy, and skin conditions. Proprietary tools, including water pharmacophore analysis, support computational biology solutions for pipeline optimization. Key programs such as ICRB-001 are in clinical trials, while others like ICRB-002 through ICRB-004 remain in earlier stages.
inCerebro's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and BeiGene.